[HTML][HTML] Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling
CA Walshe, SA Beers, RR French, CHT Chan… - Journal of Biological …, 2008 - ASBMB
The anti-CD20 monoclonal antibody (mAb) rituximab is now routinely used for the treatment
of non-Hodgkins lymphoma and is being examined in a wide range of other B-cell disorders,
such as rheumatoid arthritis. Despite intensive study, the mechanism of action still remains
uncertain. In the current study, anti-CD20 mAb-induced calcium signaling was investigated.
Previously, we grouped anti-CD20 mAbs into Type I (rituximab-like) and Type II (B1-like)
based upon various characteristics such as their ability to induce complement activation and …
of non-Hodgkins lymphoma and is being examined in a wide range of other B-cell disorders,
such as rheumatoid arthritis. Despite intensive study, the mechanism of action still remains
uncertain. In the current study, anti-CD20 mAb-induced calcium signaling was investigated.
Previously, we grouped anti-CD20 mAbs into Type I (rituximab-like) and Type II (B1-like)
based upon various characteristics such as their ability to induce complement activation and …